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ABSTRACT
Non-viral vectors are promising vehicles for gene
therapy but delivery of plasmid DNA to post-mitotic
cells is challenging as nuclear entry is particularly
inefficient. We have developed and evaluated a
hybrid mRNA/DNA system designed to bypass the
nuclear barrier to transfection and facilitate cyto-
plasmic gene expression. This system, based on
co-delivery of mRNA(A64) encoding for T7 RNA
polymerase (T7 RNAP) with a T7-driven plasmid,
produced between 10- and 2200-fold higher gene
expression in primary dorsal root ganglion neuronal
(DRGN) cultures isolated from Sprague–Dawley rats
compared to a cytomegalovirus (CMV)-driven plas-
mid, and 30-fold greater expression than the
enhanced T7-based autogene plasmid pR011. Cell-
free assays and in vitro transfections highlighted
the versatility of this system with small quantities
of T7 RNAP mRNA required to mediate expression
at levels that were significantly greater than with the
T7-driven plasmid alone or supplemented with T7
RNAP protein. We have also characterized a num-
ber of parameters, such as mRNA structure, intra-
cellular stability and persistence of each nucleic
acid component that represent important factors
in determining the transfection efficiency of this
hybrid expression system. The results from this
study demonstrate that co-delivery of mRNA is a
promising strategy to yield increased expression
with plasmid DNA, and represents an important step
towards improving the capability of non-viral vectors
to mediate efficient gene transfer in cell types, such
as in DRGN, where the nuclear membrane is a
significant barrier to transfection.
INTRODUCTION
The concept of gene therapy is attractive and nearly two dec-
ades of research have demonstrated its potential as either
a standalone treatment or an adjuvant therapy for inheritable
and acquired diseases. Despite the signiﬁcant advances made,
there has been limited success in the clinical application of
gene therapy, which is largely attributable to a lack of safe
and efﬁcient gene transfer (1–3). Synthetic vectors based on
polycations or cationic lipids are promising vectors for gene
delivery as they are relatively safe and can be readily modi-
ﬁed by the incorporation of ligands for targeting to speciﬁc
cell types. However, the levels of gene expression mediated
by synthetic vectors are low compared to viral vectors (4).
A major factor restricting transgene expression is inefﬁcient
transfer of DNA from the cytoplasm to the nucleus with
only 1% of polyplex DNA reaching the nucleus follow-
ing cytoplasmic microinjection (5). The majority of cells
in vivo are post-mitotic or quiescent, and transfection rates
are particularly poor in these cell types as there is limited
breakdown of the nuclear envelope (6,7). Recent improve-
ments in non-viral vectors, such as lipid/peptide vectors (8)
and DNA nanoparticles consisting of a single molecule of
DNA (9), have enhanced transgene expression levels in
non-dividing cells. However, it is clear that further improve-
ments in the design of non-viral vectors are required to
achieve the expression levels required for a broad range of
therapeutic applications.
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to modify the nucleic acid payload delivered by the non-viral
vector. To promote nuclear uptake of DNA, for instance,
nuclear localization sequence (NLS) peptides have been
utilized to exploit intracellular transport mechanisms (10).
However, the results to date have been largely disappointing.
A 3-log increase in luciferase reporter activity was reported
in one study following ligation of an oligonucleotide–NLS
conjugate to one or both ends of a linear DNA molecule,
although no conclusive localization or mechanistic data was
given (11). Whereas, we (12) and others (13) found no effect
or only modest increases in gene expression following link-
age of NLS peptides to DNA.
Non-viral vectors have also been used to deliver mRNA
instead of plasmid DNA (14,15), or T7-based autogene
plasmids utilizing bacteriophage T7 RNA polymerase (T7
RNAP) to mediate cytoplasmic expression (16–18). The
main advantage of delivering mRNA is that upon entry into
the cytoplasm it is immediately translated, and so it can
be used to successfully express proteins in post-mitotic, quies-
cent and slowly-dividing cells (14,19,20). The relative
instability of mRNA, however, restricts the duration of gene
expression and therapeutic applications have so far been
limited. By comparison, the efﬁciency of T7-based autogene
plasmids has gradually increased since their initial develop-
ment over a decade ago. In most contemporary systems the
cytomegalovirus (CMV) promoter has been incorporated to
enable easier bacterial ampliﬁcation of the plasmid. This has
meant that there is now a requirement for nuclear entry to
trigger the autogene, which is likely to compromise the utility
of these systems in non-dividing cells (21,22).
Here, we report on the development and evaluation of a
hybrid mRNA/DNA system, designed to bypass the nuclear
barrier to transfection and facilitate cytoplasmic gene expres-
sion. In particular, we demonstrate that a hybrid mRNA/DNA
cassette utilizing T7 RNAP mRNA represents a versatile
and efﬁcient system for mediating cytoplasmic expression
in post-mitotic dorsal root ganglion neuronal (DRGN)
cultures, where the nuclear membrane is a signiﬁcant barrier
to transfection.
MATERIALS AND METHODS
Cell lines and primary cells
Human lung carcinoma cells (A549, ATCC #CCL-185) and
human prostate carcinoma cells (PC-3, ATCC #CRL-1435)
were maintained in DMEM, without sodium pyruvate, with
L-glutamine (PAA Laboratories, Somerset, UK) supple-
mented with 10% fetal calf serum (FCS, PAA Laboratories,
Somerset, UK) and 1% penicillin streptomycin solution. All
cells were incubated at 37 C in a 5% CO2 humidiﬁed environ-
ment. DRGN cultures were prepared from adult Sprague–
Dawley rats. Brieﬂy, spinal ganglia were removed aseptically,
washed twice in Neurobasal-A media (Invitrogen, Paisley,
UK) and digested in 0.125% collagenase/supplemented
Neurobasal-A (2% B27 supplement, 0.5 mM L-glutamine
and 0.5% gentimicin) for 2 h at 37 C. Disassociated spinal
ganglia cells were removed from the collagenase, washed in
Neurobasal-A and puriﬁed by centrifugation for 10 min at
120 g on a 15% BSA column.
Sources of nucleic acids
Plasmid DNA was grown in Escherichia coli and puriﬁed
using endotoxin-free Qiagen maxiprep kits (Crawley, West
Sussex, UK). The concentration and purity of DNA was
checked on a spectrophotometer at A260 and A280 absorbance
wavelengths. The reporter gene construct pCMVLuc1 was a
gift from Dr Manfred Ogris (Munich, Germany). The design
and construction of cytoplasmic expression plasmids used in
this study are shown in Figure 1A and Supplementary
Figures 1–2. Brieﬂy, pCMV/T7-T7pol was constructed as
described by Brisson et al. (21); pCMV/T7-T7pol(A64) is a
modiﬁed version of pCMV/T7-T7pol into which an oligonu-
cleotide containing 64 adenylate residues was inserted
into the BamHI–NotI restriction sites downstream from the
T7 RNAP gene; pT7Luc, also known as pEMCLucbgAn
(17), contains the Photinus pyralis luciferase gene ﬂanked
upstream by the T7 promoter, and pR011 contains the T7
RNAP gene driven by CMV and triple phage promoters
(T7, T3 and SP6), and the luciferase gene driven by a T7
promoter (22).
Production of mRNA
In vitro transcription to produce capped mRNA encoding
T7 RNAP protein was performed using the Ribomax 
large scale mRNA production system (Promega, Southamp-
ton, UK), with the addition of either a standard
m7G(50)ppp(50)G cap, or anti-reverse cap analogue (Ambion)
substituted for a portion of the rGTP at a 4:1 ratio, as recom-
mended by the manufacturer. A poly(A) tailing kit (Ambion)
was used as indicated to add a >200 base poly(A) tail to cell-
free transcribed mRNA prior to puriﬁcation. The synthesis of
mRNA encoding enhanced green ﬂuorescent protein (EGFP)
and luciferase has been described previously (20). Products
were checked by denaturing gel electrophoresis.
Cell-free translation systems
The standard rabbit reticulocyte lysate (RRL) cell-free system
(Promega) was used to characterize translation products
from mRNA encoding T7 RNAP protein. Reactions were
incubated at 30 C for 90 min, prior to storage at  80 C
and performed following the manufacturer’s instructions.
The cell-free RRL translation system was also used in a stan-
dard cell-free transcription/translation system to analyse
expression of T7 RNAP from mRNA by subsequent expres-
sion and detection of luciferase protein from plasmid
pT7Luc. T7 RNAP protein was also added with pT7Luc to
the RRL cell-free system and levels of luciferase activity
detected. Reaction mixtures were incubated at 30 C and
5 ml aliquots removed at speciﬁc time points and assayed
for luciferase activity with results expressed in relative light
units (RLU).
Quantitative RT–PCR analysis of mRNA
A quantitative RT–PCR assay was used to quantify intracel-
lular levels of T7 RNAP mRNA at speciﬁc time points post-
transfection. In brief, total RNA was extracted using the
RNeasy mini kit (Qiagen) from A549 cells co-transfected
with T7 RNAP mRNA (100 ng) and pT7Luc (400 ng). A
total of 150 ng of total RNA was reverse transcribed to
cDNA using random hexamer primers and multiscribe
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of T7 forward primer (50-TCACGACTCCTTCGGTACCAT-
30), T7 reverse primer (50-CATAGTTTCGCGCACTGCTTT-
30), T7 probe labelled with 50 FAM and 30 TAMRA
(50-CGGCTGACGCTGCGAACCTGTT-30) and qRT–PCR
mastermix, 40 cycles of a two step thermal cycling protocol
(denature: 95 C, 15 s; anneal/extend: 60 C, 1 min) was
performed using the Applied Biosystems 7000 Sequence
Detection System. 18S Ribosomal RNA was detected using
appropriate primers and probe (Applied Biosystems) to dem-
onstrate that a similar amount of total RNA was used in each
qRT–PCR. The amount of T7 RNAP mRNA present in each
sample was then calculated from a T7 RNAP mRNA standard
curve generated by performing qRT–PCR on lysate samples
prepared from mock-transfected cells spiked with a known
amount of T7 RNAP mRNA (equivalent to 0.1, 1, 10 and
100 ng mRNA per well).
Transfection studies
Plasmid DNA and/or mRNA were added to a polypropylene
microcentrifuge tube at a ﬁnal concentration of 50 mg/ml in
Figure 1. Characterization of mRNA used in study. (A) Plasmid pCMV/T7-T7pol was constructed as described in Supplementary Figure 1 (21). pCMV/T7-
T7pol(A64) is a modified version of pCMV/T7-T7pol into which an oligonucleotide containing 64 adenylate residues was inserted into the BamHI–NotI
restriction sites immediately downstream from the T7 RNAP gene. (B) Cell-free transcribed mRNA was denatured at 80 C for 10 min and analysed on an
ethidium bromide stained 1% reducing agarose gel (1 mg RNA per lane) and visualized by ultraviolet (UV) illumination. The relative positions of mRNA bands
are indicated. (C) Western blot analysis of T7 RNAP protein translated from T7 RNAP mRNA using the RRL system (Promega). T7 RNAP protein was
detected using a primary mouse monoclonal antibody raised against T7 RNAP protein (Novagen, CA) and a secondary anti-mouse antibody IgG horseradish
peroxidase (HRP) conjugate. Recombinant T7 RNAP protein was used as a positive control.
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quots were thawed from  80 C, heated at 80 C for 10 min
and chilled on ice for 2 min prior to addition. DOTAP was
then added to nucleic acids, unless otherwise stated, at a
(w/w) ratio of ﬁve and mixed by pipetting the solution up
and down ·5 prior to use. Lipoplexes were added directly
to a 48-well plate containing 3–4 · 10
4 cells per well in
120 ml DMEM or optimem without FCS or supplement
(cells were plated 24 h before transfection). Freshly isolated
DRGN cultures were seeded at a density of  1500 cells per
well in supplemented Neurobasal-A. After 4 h, the medium
was discarded and replaced with 500 ml per well of
either DMEM containing 10% FCS, or supplemented
Neurobasal-A. Cells were cultured for various times prior
to analysis of reporter gene expression as indicated. Cell
viability was determined using the MTS assay (Promega)
after exposure to free DOTAP or lipoplexes as indicated
and normalized to values obtained in their absence as
described previously (23).
Assay of reporter genes
Luciferase expression following transfection was measured
by a luminescence assay using cell lysates. The culture med-
ium was discarded and cell lysates harvested after incubation
of cells for 30 min at  80 C in 100 ml lysis reagent buffer
(Promega) before being thawed at RT. The lysate was
mixed well by pipetting and 20 ml was diluted into 25–
100mlofluciferaseassayreagent(Promega).Theluminescence
was integrated over 10 s on a Victor
2 1420 Multilabel Counter
(Wallac, Bucks, UK) or a Lumat LB9507 (Berthold Instru-
ments,UK)andtheresultsexpressedasRLUpermgofcellpro-
tein, determined using the Advanced Protein Assay
(Cytoskeleton,Denver).AnalysisofEGFPexpressionwascar-
riedoutonaCoulterEpicsXLﬂowcytometer.Cellsweretryp-
sinized at appropriate times after transfection, washed with
phosphate-buffered saline (PBS) and then ﬁxed in 2%
paraformaldehyde. EGFP was excited using the 488 nm line
of an Argon laser and emitted light collected at 520 nm
(green ﬂuorescence) and 575 nm (red ﬂuorescence) to enable
correction for autoﬂuorescence by diagonal gating. Back-
ground ﬂuorescence and autoﬂuorescence were determined
using mock treated cells. The software programme WinMDI
was used to analyse data and expressed as the percentage of
EGFP-positive cells. Statistical analysis was performed on at
least three samples for each transfection by calculating the
mean value, SD and using an unpaired t-test where appropriate
(www.graphpad.com/quickcalcs/ttest1.cfm).
Western blot analysis
Cells were lysed in M-PER cell lysis buffer (100 ml, Perbio
Science, Northumberland, UK) containing complete protease
inhibitor cocktail (Roche, East Sussex, UK). The lysates were
normalized for protein concentration using the Advanced
Protein Assay (Cytoskeleton) and stored at  70 C until
used for western blot analysis. Each sample (20 mg total pro-
tein) was heated at 90 C for 5 min and separated on a 9%
SDS–polyacrylamide gel (Invitrogen). Proteins were trans-
ferred to nitrocellulose membranes overnight and blocked
for 90 min at room temperature in PBS containing 5%
non-fat milk. Membranes were blotted with the relevant
primary antibody for 90 min, washed in PBS containing
0.1% Tween and the secondary antibody added. For detection
LumiGLO  chemiluminescent substrate (Upstate) was added
and chemiluminescence detected using the MultiImage 
light cabinet and Fluorchem 8800 software (Alpha
Innotech, CA).
RESULTS
Production and analysis of T7 RNAP mRNA
Construction of pCMV/T7-T7pol and insertion of a 64 bp
oligonucleotide to prepare pCMV/T7-T7pol(A64) are out-
lined in Figure 1A and Supplementary Figure 1. We ﬁrst pre-
pared mRNA encoding T7 RNAP protein from NotI
linearized pCMV/T7-T7pol and pCMV/T7-T7pol(A64) to
investigate whether it can trigger expression of co-delivered
plasmid DNA, and improve the efﬁciency of T7-based cyto-
plasmic plasmids. Denaturing electrophoretic analysis
showed that pCMV/T7-T7pol(A64) produced mRNA of the
expected size (2899 nt) that was slightly longer than the tran-
script derived from pCMV/T7-T7pol (2880 nt, Figure 1B). To
conﬁrm that transcribed mRNA encoded T7 RNAP protein,
T7 RNAP mRNA containing the 64 bp poly(A) sequence
was translated utilizing the RRL system. Immunoblotting
for the T7 RNAP protein using a mouse anti-T7 RNAP
monoclonal IgG antibody gave a band of  100 kDa that
was similar in size to recombinant T7 RNAP protein, indicat-
ing that T7 RNAP mRNA had been translated successfully
(Figure 1C).
A cell-free transcription/translation assay incorporating the
reporter plasmid pT7Luc was performed next to conﬁrm that
T7 RNAP protein translated from mRNA was biologically
functional. Incubation of pT7Luc in the presence of T7
RNAP protein resulted in luciferase expression that was
dose-dependent upon the amount of T7 RNAP protein
added (Figure 2A). The addition of 100 U of T7 RNAP pro-
tein, for instance, generated a maximum of  1.7 · 10
4 RLU
after 390 min. By comparison, plasmid pT7Luc incubated
with 1 mg of T7 RNAP mRNA gave  100-fold higher
level of luciferase expression (1.7 · 10
6 RLU, Figure 2B).
These results demonstrated that T7 RNAP protein translated
from T7 RNAP mRNA was functional and mediated
luciferase expression at levels up to 100-fold greater than
using T7 RNAP protein directly. However, it is interesting
to note that after shorter times T7 RNAP protein mediated
higher expression levels than T7 RNAP mRNA. For example,
after 30 min, expression driven by T7 RNAP protein (2.0 ·
10
3 RLU) was 10-fold greater than T7 RNAP mRNA
(2.0 · 10
2 RLU, Figure 2). This is likely to reﬂect the require-
ment for translation of T7 RNAP mRNA to occur prior to
transcription of the luciferase gene.
Co-delivery of mRNA encoding T7 RNAP protein
enhances transgene expression
Having established the functional activity of mRNA encoding
T7 RNAP in a cell-free assay, we next evaluated the efﬁci-
ency of T7 RNAP mRNA to trigger luciferase expression
from plasmid pT7Luc in A549 and PC-3 cells. Initial trans-
fections showed that the level of luciferase expression
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maximum of 1.0 · 10
8 RLU/mg protein in A549 cells and
1.9 · 10
8 RLU/mg protein in PC-3 cells (Figure 3A). By
comparison, only background levels of luciferase expression
( 1.0 · 10
4 RLU/mg protein in A549 cells) were detected in
the absence of T7 RNAP mRNA. The amount of pT7Luc
used to transfect A549 and PC-3 cells was also an important
determinant of luciferase expression. Expression mediated by
125 ng of T7 RNAP mRNA increased with the dose of
pT7Luc up to the maximum amount of 500 ng added to
A549 ( 9.4 · 10
7 RLU/mg protein) and PC-3 ( 2.3 · 10
8
RLU/mg protein) cells (Figure 3B). Doubling the quantity
of plasmid pT7Luc from 250 to 500 ng resulted in a 4-fold
increase in expression in A549 cells and a 6-fold increase
in PC-3 cells.
Transfections were next performed to directly compare
the efﬁciency of T7 RNAP mRNA with T7 RNAP protein
to mediate luciferase expression from pT7Luc. Preliminary
experiments indicated that 10–50 U of T7 RNAP protein
were required to produce maximum expression levels with
500 ng of pT7Luc in A549 ( 3.0 · 10
6 RLU/mg protein)
and PC-3 ( 2.0 · 10
7 RLU/mg protein) cells (Figure 3C).
Subsequent transfections to compare T7 RNAP mRNA
with T7 RNAP protein in the same experiment showed
that co-delivery of 125 ng T7 RNAP mRNA with 500 ng
of pT7Luc gave 5.2-fold and 6.7-fold greater luciferase
expression compared to T7 RNAP protein at a dose of
100 U in A549 and PC-3 cells, respectively (Supplementary
Figure 3). Taken together, these results demonstrate the
superior transfection properties of cytoplasmic expression
systems triggered by T7 RNAP mRNA compared to T7
RNAP protein.
Parameters influencing the efficiency of the T7 RNAP
mRNA/pT7Luc expression system
We next examined several parameters that have been reported
to affect the efﬁciency of nucleic acid-based expression sys-
tems, including the structure of mRNA, intracellular stability,
time course of delivery and cytotoxicity (4,24,25). First, we
compared the efﬁciency of T7 RNAP mRNA containing dif-
ferent structural components to trigger luciferase expression
from co-delivered pT7Luc in A549 and PC-3 cells.
Figure 4A shows that T7 RNAP mRNA modiﬁed with either
m7G(50)ppp(50)G (Cap), or an anti-reverse cap analogue
(ARCA), and a poly(A64) tail produced the highest levels
of luciferase gene expression ( 1.2 · 10
7 RLU/mg protein
in A549 cells). However, reporter gene expression was abol-
ished by  80% corresponding to a 4.8–5.6-fold decrease
using capped T7 RNAP mRNA lacking a poly(A64) tail.
The importance of the poly(A) tail was further demonstrated
by a 2.2 to 3.0-fold increase in gene expression when a
poly(A) tail of  200 residues was added to capped T7
RNAP mRNA lacking the A64 tail with a poly(A) tailing
kit (Figure 4A).
To evaluate the intracellular stability and persistence of T7
RNAP protein and pT7Luc, we transfected A549 cells with
the relevant nucleic acid components at different time points.
For instance, expression levels were abolished by >240-fold
(4.9 · 10
4 RLU/mg protein) when A549 cells were trans-
fected with 500 ng pT7Luc 12 h prior to transfection with
125 ng T7 RNAP mRNA compared to that detected when
both T7 RNAP mRNA and pT7Luc were transfected together
( 1.2 · 10
7 RLU/mg protein, Figure 4B). In contrast,
luciferase expression (7.7 · 10
6 RLU/mg protein) detected
when T7 RNAP mRNA transfection preceded pT7Luc
transfection was still  65% of that when both nucleic acids
were transfected together, indicating that the half-life of the
T7 RNAP protein was at least 12 h (Figure 4B). This is in
agreement with published studies that have estimated the
half-life of T7 RNAP protein in 293 cells to be >24 h (26).
A qRT–PCR assay was next developed to evaluate the per-
sistence of T7 RNAP mRNA in A549 cells and used to
calculate the quantity of T7 RNAP mRNA present in trans-
fected cultures over a time course of 24 h. Figure 4C
shows that the signal from T7 RNAP mRNA decreased
over time (exponential decay) with an estimated half-life in
A549 cells of 4.79 h. Finally, cell viability assays using
Figure 2. Cell-free assays demonstrate enhanced luciferase activity with T7 RNAP mRNA. (A) T7 RNAP protein at a dose of 1 U (diamonds) or 100 U (squares)
was incubated with pT7Luc (1.0 mg) in the presence of RRL. (B) T7 RNAP mRNA at a dose of 10 ng (diamonds) or 100 ng (squares) was incubated with pT7Luc
(1.0 mg) in the presence of RRL. In both experiments pT7Luc was incubated in RRL in the absence of T7 RNAP protein or T7 RNAP mRNA (triangles) as a
negative control. Luciferase activity was measured at the indicated time points. Results are shown as a mean and SD from at least three samples.
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(100 ng) complexed with DOTAP or DOTAP alone gave neg-
ligible toxicity (Figure 4D). Co-delivery of T7 RNAP mRNA
with pT7Luc also gave minimal toxicity with between 88 and
91% cells remaining viable after 24 h, depending on the dose
of plasmid DNA, compared to mock-transfected cells.
Altogether, these results characterize a number of para-
meters that can inﬂuence the efﬁciency of the T7 RNAP
mRNA/pT7Luc expression system. In particular, the intracel-
lular stability of plasmid DNA appears to be the most impor-
tant determinant in limiting gene expression, and not the
duration of expression or stability of the T7 RNAP protein.
Enhanced transfection efficiency of mRNA triggered
systems in DRGN cultures
We next examined whether cytoplasmic expression systems
triggered by mRNA can efﬁciently transfect primary DRGN
cultures, where the majority of cells are likely to be post-
mitotic or slowly-dividing. In preliminary experiments,
ﬂuorescence microscopy and ﬂow cytometry were used to
evaluate the ability of mRNA or plasmid DNA encoding
EGFP to transfect DRGN cultures freshly isolated from
adult Sprague–Dawley rats. Figure 5A and B show that a
high proportion (>50%) of phenotypically identiﬁable
DRGN in culture were transfected with EGFP mRNA. In con-
trast, no EGFP-positive cells were detected using mRNA
encoding for luciferase (LUC mRNA) as a control
(Figure 5A). Furthermore, we observed <2% EGFP-positive
cells in DRGN cultures with the CMV-driven plasmid
pEGFPN1 (Figures 5B and 6).
The transfection efﬁciency of T7 RNAP mRNA with
pT7Luc was then compared against the CMV-driven plasmid
pCMVLuc1 in DRGN cultures and A549 cells. In primary
DRGN cultures, pCMVLuc1 was a particularly inefﬁcient
vector with luciferase expression no higher than that seen
Figure 3. Comparison of luciferase expression mediated by T7 RNAP mRNA and T7 RNAP protein. A549 (white bars) and PC-3 (grey bars) cells were
transfected with (A) 500 ng pT7Luc with increasing quantities of T7 RNAP mRNA (0–500 ng), (B) 125 ng T7 RNAP mRNA with increasing quantities of
pT7Luc (0–500 ng), or (C) 500 ng pT7Luc with increasing quantities of T7 RNAP protein (0–200 U) as indicated. For all transfections 3.5 · 10
4 cells were plated
per well 24 h prior to transfection and DOTAP used at a (w/w) ratio of five relative to the nucleic acid component. At 12 h post-transfection cells were lysed and
luciferase activity measured using the Victor
2 multilabel counter. Results are shown as a mean and SD from at least three samples.
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4 RLU/mg protein;
Figure 5C). By comparison, transfection of DRGN cultures
with the T7 RNAP mRNA triggered system gave >100-fold
increase in luciferase activity (1.3 · 10
6 RLU/mg protein;
P ¼ 0.0185). This level of reporter gene expression was
similar to that obtained using the same system in A549
cells (4.2 · 10
6 RLU/mg protein). In contrast, in rapidly
dividing A549 cells, where nuclear access was relatively
easy the functionality of pCMVLuc1 was evident, with high
luciferase activity (7.8 · 10
6 RLU/mg protein) (Figure 5C).
Further analysis using a more sensitive luciferase assay
showed that transfection of DRGN cultures with the T7
RNAP mRNA triggered system gave >2200-fold increase in
luciferase activity (2.2 · 10
8 RLU/mg) compared to
pCMVLuc1 (9.9 · 10
4 RLU/mg, Supplementary Figure 4).
Evaluation of the time course of gene expression in DRGN
cultures showed signiﬁcant luciferase activity with the T7
RNAP mRNA triggered system after 6 h that increased up
Figure 4. Characterization of the T7 RNAP mRNA/pT7Luc expression system. (A) A549 (white bars) and PC-3 (grey bars) cells were transfected with 400 ng
pT7Luc with 100 ng T7 RNAP mRNA modified with either m7G(50)ppp(50)G (Cap), an anti-reverse cap analogue (ARCA), a poly(A64) tail or a poly(A) tail of
 200 residues (A200) as indicated. (B) A549 cells were transfected with 500 ng pT7Luc (time 0 h) prior to transfection 12 h later with 125 ng T7 RNAP mRNA
(time 12 h), or vice versa as indicated. Cells were lysed after a further 12 h and luciferase activity measured. In control experiments, A549 cells were transfected
with both pT7Luc and T7 RNAP mRNA at time 0 h, and lysed 12 h later. (C) A549 cells were transfected with 400 ng pT7Luc and 100 ng T7 RNAP mRNA, and
at the indicated time point lysed and total RNA extracted. A qRT–PCR assay was used to quantify the amount of T7 RNAP mRNA present (pg) as described in
Materials and Methods. (D) A549 cells were incubated in the presence of DOTAP alone, or the indicated nucleic acid complex for 4 h in serum-free media.
The media was discarded and replaced with fresh media containing 10% FCS and the MTS assay used to assess cellular viability after 24 h. For all transfections
3.5 · 10
4 cells were plated per well 24 h prior to transfection and DOTAP used at a (w/w) ratio of five relative to the nucleic acid component. At 24 h post-
transfection, unless otherwise indicated, cells were lysed and luciferase activity measured using the Victor
2 multilabel counter. Results are shown as a mean and
SD from at least three samples. (***P < 0.0001).
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RNAP mRNA triggered system produced signiﬁcantly
greater luciferase activity than pCMVLuc1 in the range of
13- to 634-fold (P < 0.05, Figure 5D).
Previously, pCMVLuc1 has been shown to be highly active
in primary rat oligodendrocytes when delivered using a par-
ticle bombardment gene delivery approach, which suggests
that in this study the poor activity of the plasmid alone was
due to limited access to the nucleus rather than inactivity of
the CMV promoter or the pCMVLuc1 vector in rat cells (27).
Hence, these results demonstrate that cytoplasmic expression
systems triggered by mRNA are efﬁcient in transfecting post-
mitotic or slowly-dividing cells, especially in cell types that
are resistant to gene transfer using conventional CMV pro-
moter driven vectors requiring nuclear entry.
Improved efficiency of T7-based autogene systems with
T7 RNAP mRNA
We next investigated whether the efﬁciency of cytoplasmic
expression systems based on autogene plasmids containing
Figure 5. Enhanced expression triggered by T7 RNAP mRNA in DRGN cultures. (A) Fluorescence images of DRGN cultures expressing EGFP following
transfection with either (i) luciferase (LUC) mRNA, or (ii) EGFP mRNA complexed with DOTAP at (w/w) ratio of 4. Phase-contrast images of transfected
DRGN cultures are shown in the right-hand column. The relative positions of DRGN in culture are indicated by arrowheads. (B) Time course of gene expression
following transfection of DRGN cultures with either EGFP mRNA (triangles), or pEGFPN1 (squares) complexed with DOTAP at (w/w) ratio of 5. EGFP
expression was measured at the indicated time point by flow cytometry analysis. (C) A549 cells (white bars) and freshly isolated DRGN cultures (grey bars)
were transfected with pCMVLuc1 (375 ng), pT7Luc (375 ng) with T7 RNAP mRNA (150 ng), or pT7Luc (375 ng) with T7 RNAP protein (100 U) as indicated.
In control experiments cells were transfected with either pT7Luc (375 ng), or T7 RNAP mRNA (150 ng) alone. At 12 h post-transfection cells were lysed and
luciferase activity measured. (D) Freshly isolated DRGN cultures (1.5 ·10
3 cells/well) were transfected with DOTAP at (w/w) ratio of 5 containing either
pCMVLuc1 (375 ng), or pT7Luc (375 ng) with T7 RNAP mRNA (150 ng). At the time points indicated, cells were lysed and assayed for luciferase expression
using the Victor
2 multilabel counter. Results are shown as a mean and SD from at least three samples. (***, P < 0.002, **, P < 0.02; *, P < 0.05).
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of the T7 RNAP protein, were also improved by co-delivery
ofT7RNAPmRNA.Fortheseexperiments,weusedanenhan-
ced autogene plasmid pR011 (Supplementary Figure 2),
which was recently developed by Finn et al. (22). Enhance-
ments to plasmid pR011 included an IRES sequence located
between the bacteriophage promoters and the T7 RNAP gene,
and the incorporation of a luciferase expression cassette.
Using plasmid pR011 in BHK cells, Finn et al. (22) have
demonstrated levels of reporter gene expression that were
20-fold higher than standard CMV-based nuclear expression
systems. In addition, direct evidence was given for an expo-
nential, autocatalytic increase in gene expression using
autogene-based plasmids. However, pR011 is still limited
by a requirement for nuclear entry to drive initial T7 RNAP
production to trigger the autogene.
The schematic in Figure 7A outlines the principle of co-
delivering T7 RNAP mRNA to trigger expression of the
luciferase reporter gene from cytoplasmic expression plas-
mids pR011 and pT7Luc. The ability of T7 RNAP mRNA
to improve the transfection efﬁciency of pR011 was evident
in A549 cells with a 2.7-fold (P ¼ 0.0026) and 3.4-fold
increase (P < 0.0001) in luciferase expression observed
after 24 and 48 h, respectively, compared to pR011 alone
(Figure 7B). Transfection of primary DRGN cultures with
pR011 in the presence of T7 RNAP mRNA also increased
luciferase expression after 24 h (4.8-fold) compared to
pR011 alone (P ¼ 0.0131, Figure 7C). By comparison, trans-
fection of DRGN cultures with pT7Luc and T7 RNAP mRNA
gave >30-fold higher level of luciferase expression than
pR011 (P < 0.05, Figure 7C). These results demonstrate
that T7 RNAP mRNA can also be used successfully to trigger
T7-based autogene plasmids and increase gene expression in
both rapidly dividing cell lines and primary cultures of post-
mitotic DRGN. Although in DRGN cultures combining
a simple T7-driven expression plasmid with T7 RNAP
mRNA gave signiﬁcantly greater gene expression than the
T7-based autogene plasmid, either with or without T7
RNAP mRNA.
DISCUSSION
A prerequisite for gene transfer with synthetic vectors is the
efﬁcient delivery of exogenous nucleic acids to the nucleus.
This goal is challenging as nuclear entry is particularly inef-
ﬁcient in post-mitotic or slowly-dividing cells since there is
limited breakdown of the nuclear envelope (6,7). In this
study, we used a hybrid mRNA/DNA system to facilitate
cytoplasmic gene expression and bypass problems associated
with the nuclear barrier to transfection. In primary DRGN
cultures, for example, co-delivery of T7 RNAP mRNA with
pT7Luc produced between 10- and 2200-fold higher gene
expression compared to the CMV-driven plasmid,
pCMVLuc1 and >30-fold increase compared to an enhanced
T7-autogene plasmid pR011. In addition, only a small quan-
tity of mRNA was required to mediate signiﬁcant gene
expression. In A549 cells, for instance, co-delivery of 10 ng
of T7 RNAP mRNA with pT7Luc was sufﬁcient to mediate a
3-log increase in luciferase activity. These properties demon-
strate that the combination of T7 RNAP mRNA with a T7-
driven DNA cytoplasmic expression plasmid represents a
powerful and versatile non-viral approach for mediating
gene expression.
The co-delivery of plasmid DNA with T7 RNAP protein is
one of the simplest and most widely used systems to achieve
cytoplasmic gene expression. This approach, however, has
been shown to be relatively inefﬁcient even in cultured
cells (28), with low levels of protein transduction likely to
be a limiting factor. Another potential problem is immune
recognition of the T7 RNAP protein that will hinder repeated
administration in vivo (21). Therefore, the major advantages
of using the hybrid mRNA/DNA system are that problems
of inefﬁcient protein transduction and immune responses
associated with repeat administration of the T7 RNAP protein
will be diminished as it is a non-viral formulation based
solely on nucleic acids. Preliminary results from a cell-free
assay demonstrated that co-incubation of T7 RNAP mRNA
with pT7Luc was more efﬁcient than using T7 RNAP protein,
with up to a 100-fold increase in luciferase expression. This
trend was repeated in A549 cells and primary DRGN
cultures (data not shown) with up to a 6.7-fold higher level
of expression achieved by co-delivery of pT7Luc with T7
RNAP mRNA rather than T7 RNAP protein. It is likely
that ampliﬁcation of the T7 RNAP protein by multiple rounds
Figure 6. Inefficient transfection of DRGN cultures with pEGFPN1. (A)
Fluorescence images of DRGN cultures expressing EGFP following
transfection with pEGFPN1 complexed with JetPEI. The right-hand column
shows the fluorescence image overlaid onto the phase-contrast image.
The relative positions of EGFP-positive DRGN are indicated by arrowheads.
(B) DRGN cultures were transfected with 500 ng of pEGFPN1 complexed
with JetPEI at the indicated N:P ratio. DRGN cultures were maintained
in supplemented Neurobasal media. EGFP expression was measured after
48 h by flow cytometry. Results are shown as mean and SD from at least
three samples. We observed <2% transfection of DRGN cultures with
pEGFPN1 using either JetPEI, DOTAP (data not shown), Lipofectamine
2000  (Invitrogen, data not shown) or GeneShuttle-40 (Qbiogene, data not
shown) as the transfection reagent.
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towards mediating higher gene expression compared to
using a static quantity of T7 RNAP protein.
We also used T7 RNAP mRNA instead of plasmid DNA
encoding the T7 RNAP gene as it does not require nuclear
uptake for expression, and translation occurs almost immedi-
ately upon entry into the cytoplasm. This is especially impor-
tant in post-mitotic or slowly-dividing cells where access of
plasmid DNA to the nucleus will be limited. The incorpora-
tion of mRNA into the hybrid expression system therefore
Figure 7. Improved efficiency of pR011 mediated by T7 RNAP mRNA. (A) Schematic comparing T7 RNAP mRNA triggered expression of pR011 with
pT7Luc. Luciferase protein is produced following binding of T7 RNAP protein to the pT7 promoter and subsequent transcription/translation of the luciferase
reporter gene. In pR011, binding of T7 RNAP protein to the pT7 promoter upstream of the T7 RNAP gene leads to autocatalytic amplication of T7 RNAP
protein. (B) A549 cells (3.5 ·10
4/well) were transfected with pR011 (375 ng) either alone or with T7 RNAP mRNA (150 ng) as indicated. Cells were lysed after
24 h (white bars) or 48 h (grey bars) and luciferase activity measured. (C) Freshly isolated DRGN cultures (1.5 ·10
3 cells/well) were transfected with the
indicated plasmid (375 ng) either in the presence or absence of T7 RNAP mRNA (150 ng). Cells were lysed after 24 h and luciferase activity measured using the
Victor
2 multilabel counter. Results are shown as a mean and SD from at least three samples. (***, P < 0.0001; **, P < 0.01; *, P ¼ 0.0131).
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in a larger proportion of cells compared to a nuclear depen-
dent plasmid. Evidence for this comes from a number of stud-
ies where EGFP mRNA was shown to transfect a higher
percentage of cells, such as primary HUVEC (20) and PC-3
cells (29), compared to an EGFP expression plasmid. We also
demonstrated in this study that plasmid pEGFPN1 gave poor
levels of transfection in DRGN cultures, whereas a signiﬁ-
cantly higher proportion of cells were transfected with
EGFP mRNA.
T7-based autogene systems have the capacity to mediate
higher levels of gene expression since, after initial triggering
of the T7-autogene by T7 RNAP, further expression of T7
RNAP occurs in an autocatalytic positive feedback loop pro-
ducing high levels of the protein (16). Subsequently, the large
quantities of T7 RNAP produced can be used to mediate
expression of a co-delivered therapeutic gene. The efﬁciency
of T7-based autogene plasmids has gradually increased since
their initial development. Incorporation of the CMV promoter
into the autogene plasmid has enabled easier bacterial ampli-
ﬁcation of the plasmid, and offered a new triggering system,
independent of protein transduction (21,22). While this
approach was shown to be effective in rapidly dividing 293
cells, there is now a requirement for nuclear entry to trigger
the autogene, which is likely to compromise the utility of
these plasmids in non-dividing cells.
A signiﬁcant ﬁnding in this study was that transfection of
DRGN cultures with pT7Luc and T7 RNAP mRNA gave
>30-fold higher gene expression than the enhanced T7-
autogene plasmid pR011. We also showed in DRGN cultures
that T7 RNAP mRNA can be used to enhance gene expres-
sion mediated by pR011 with up to a 4.8-fold increase
in luciferase activity. By comparison, the enhancement
in expression with T7 RNAP mRNA was slightly lower in
A549 cells (3-fold), which may reﬂect the higher transfection
activity of pR011 in these cells due to increased nuclear entry
and subsequent triggering of the CMV promoter. The hybrid
T7 RNAP mRNA/DNA system contains important features
that will have contributed towards the superior transfection
proﬁle in primary DRGN cultures. First, the T7 RNAP
mRNA was capped and polyadenylated, and so would have
been translated more efﬁciently and have a longer half-life
than autogene derived, IRES containing transcripts. Finn
et al. (30) recently showed that IRES mediated translation
was relatively inefﬁcient compared to the cap dependent
form, with luciferase expression from IRES containing
mRNA almost 20-fold lower than from an equivalent capped
transcript. Furthermore, T7 RNAP protein produced by
mRNA translation drives efﬁcient expression from a co-
delivered reporter plasmid almost immediately, without the
need for mRNA ampliﬁcation to occur. This may provide a
critical time advantage since degradation of plasmid DNA
by cytoplasmic nucleases limits cytoplasmic expression
(5,25).
The major factor that appeared to limit expression with
the hybrid T7 RNAP mRNA/DNA system was the quantity
of plasmid DNA available as a cytoplasmic transcription tem-
plate, rather than T7 RNAP protein produced from T7 RNAP
mRNA. Doubling the quantity of pT7Luc transfected from
250 to 500 ng, for instance, resulted in a 6-fold increase in
gene expression in PC-3 cells. The inclusion of an autogene
expression cassette within the formulation was not required
as a small quantity of T7 RNAP mRNA was sufﬁcient to
drive optimal expression from co-transfected plasmid DNA.
The challenges now lie in improving the duration of trans-
gene expression and persistence of plasmid DNA, and we
are currently exploring different strategies to address these
issues, including the use of CpG-depleted plasmids to prolong
expression in vivo (31–34). It will also be necessary to deter-
mine the extent to which intracellular expression of the T7
RNAP protein leads to potential immunogenicity problems
or whether the use of a nucleic acid formulation is sufﬁcient
to diminish immune responses to the T7 RNAP protein, and
so maintain the viability of transfected cells without the use
of immunosuppressants (35).
Based on our ﬁndings in primary DRGN cultures, potential
therapeutic applications for this hybrid expression system
include the delivery of neurotrophic factors to promote
axonal regeneration, in possibly a range of neurological con-
ditions, from spinal cord injury to chronic progressive neu-
rodegenerative diseases. Recently, we demonstrated that an
effective strategy to sustain gene delivery to axotomized neu-
rons was to immobilize plasmid DNA in gene-activated mat-
rices (GAM) that were placed between the proximal and
distal stumps of severed rat optic nerves (36) or into a
lesioned rat dorsal column (37). Hence, we envisage that
GAM-mediated delivery of hybrid expression systems encod-
ing for neurotrophic factors will represent a more effective
strategy to enhance DRGN axonal regeneration in vivo than
the use of CMV-driven plasmid DNA. Furthermore, the cen-
tral nervous system has historically been designated as an
‘immunologically privileged’ site, as it lacks normal surveil-
lance by cells and mediators of the immune system. The cen-
tral nervous system therefore represents an ideal site for
delivery of non-viral vectors containing the hybrid mRNA/
DNA expression system, especially when potentially
immunogenic proteins are expressed.
In summary, the results from this study demonstrate that
co-delivery of mRNA is a promising strategy to yield
increased expression with plasmid DNA and facilitate cyto-
plasmic gene expression. Furthermore, this work represents
an important step towards the development of non-viral for-
mulations based on a hybrid mRNA/DNA system that should
prove useful for the expression of proteins in post-mitotic or
slowly-dividing cells, where the nuclear barrier represents a
signiﬁcant barrier to transfection.
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